Impact of magnetic resonance imaging visibility of prostate cancer on partial gland ablation
MRI visibility is an independent prognosticator for outcomes following focal therapy for prostate cancer. Patients with higher MRI visibility (PIRADS ≥4) are at an increased risk of treatment failure.
Authors
- Yuta Inoue (ORCID: https://orcid.org/0000-0002-0809-895X)
- Osamu Ukimura (ORCID: https://orcid.org/0000-0003-3443-3210)
- Samuel J. Peretsman (ORCID: https://orcid.org/0000-0002-9211-3680)
- Pierre Halteh
- Manju Aron
- Inderbir S. Gill (ORCID: https://orcid.org/0000-0002-5113-7846)
- Suzanne L. Palmer (ORCID: https://orcid.org/0000-0002-3492-7459)
- Jessica Cummins
- Masatomo Kaneko (ORCID: https://orcid.org/0000-0002-1205-807X)
- Lorenzo Storino Ramacciotti (ORCID: https://orcid.org/0000-0002-0615-9720)
- Andre Luis Abreu (ORCID: https://orcid.org/0000-0002-9167-2587)
- Jie Cai (ORCID: https://orcid.org/0000-0002-2691-0411)
Institutions
- University of Southern California (US)
- Cedars-Sinai Medical Center (US)
- Prostate Cancer Foundation (US)
- Kyoto Prefectural University of Medicine (JP)
- Carolina Veterinary Specialists (US)
- Oncology Specialists of Charlotte (US)
Publication Details
- Journal
- BJUI Compass
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1002/bco2.70065
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52